about
Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegenerationThe differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromesThe challenge of comorbidity in clinical trials for multiple sclerosisRecommendations for observational studies of comorbidity in multiple sclerosis.A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosisGenetic interaction of CTLA-4 with HLA-DR15 in multiple sclerosis patientsCountry, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndromeImpact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational studyPregnancy, sex and hormonal factors in multiple sclerosis.Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients.Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta.Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) studyTHC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.Glatiramer acetate in multiple sclerosis: a review.Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis.The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population.Low serum urate levels are associated to female gender in multiple sclerosis patients.Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review.Geographical variations in sex ratio trends over time in multiple sclerosis.Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study.Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisAquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificityA systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overviewComparative efficacy of switching to natalizumab in active multiple sclerosis.A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosisThe incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review.A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis.A systematic review of the incidence and prevalence of cancer in multiple sclerosis.Predictors of disability worsening in clinically isolated syndrome.Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MSA comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patientsDevelopment of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies Detection.Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)Serum levels of N-acetyl-aspartate in migraine and tension-type headache.The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.
P50
Q21131975-B4FDA9EB-6734-4FD8-9D2C-C1739C4085E8Q22252673-55F1283D-747F-417A-A399-DDE7E70FF669Q26765031-1A4B3EAD-EFFE-4A17-8CD6-96F2FB9072F8Q26766688-D0A7E482-3D0B-42DF-A4E6-E1667BBD2906Q27010175-248C8A3D-CE0E-4128-9A09-BB09404AB2DCQ28184240-78BF999F-FFC4-4B9B-968E-6DE82AA3F314Q28480907-3829863E-E711-4FB0-9BDF-7F81C7A2C059Q28730321-DF36996C-1994-46F5-9299-80894FED5A27Q30354175-63CF02B2-A885-4EFC-8FB9-BB5A5C6F2DE8Q30653549-55D25EE6-7CEA-4319-94CA-7EBA2E3D7CC2Q30817229-DDDCBA61-D8CB-4172-A3BB-4D8C72C66310Q31023886-55D870B4-0984-448E-A832-A18DA95FCE76Q31028236-83FAD06B-08F5-4B32-AAEA-2A73BB2668ABQ31038347-0F0470F8-DE17-4557-A4DF-59BA9AF7D178Q31048193-87238FA1-21BC-4E14-9239-FE79F7A59DCFQ31118802-E9606423-D862-458A-9DFC-BBD56B467292Q31141962-3926EC9D-BE2D-4777-AEC9-E60F809E1E5CQ31162052-699F436A-9281-4FF2-9B54-B425DCD9FA7FQ34109028-773A87C5-347F-4BCD-985C-E077D0B728D0Q34234374-98D7D2E4-9EB3-4F8F-B154-52F9BDCB2589Q34357957-1F5C4FE5-309F-4CC2-AA2F-5C7C3F01E4CDQ34431300-2F830303-A73E-41FA-A867-359E30767262Q34457934-2006DB37-3518-4FDB-B146-96C579812DF9Q34469310-D10E9CA7-36A2-441A-BDFD-841B397836F3Q34527935-D99137C2-2BBB-43E3-96D2-4B14FFA59C52Q34737478-9B1A5E08-FF38-463D-8500-8E4C8FB8CBB1Q35048235-8A29C00F-CA11-4BE7-946E-511DB15D7501Q35181841-CE70AAF4-C0CB-4DFB-A053-EBB1136BFFA4Q35469575-82DA7CE8-19B0-4A2C-8675-0AD689F561E9Q35501450-14B16BFB-F780-4A76-9750-135B19F8C388Q35598760-3DCD0802-C1B6-410F-A615-DA0C5A9C2A36Q35598775-9FAF0C93-C36D-48A9-894C-0290F9F9B4F9Q35598778-4C32DE68-D929-44DC-BD9F-95E53531316FQ35619185-E62C8398-4540-4FC1-A270-FE593A466BB0Q35653675-3B0C9EF2-F307-4786-A361-719901A45DDBQ35809567-D7721FA5-8D7E-4E1D-8842-40C8873C9913Q35850484-B9B63D2B-BC5A-486A-BE0C-779F454805FDQ35895287-B25F994F-C963-44CE-BD56-00872F39DFB9Q36052148-6F4EBE46-8FAF-480C-8D1B-F547E6F08CE7Q36062456-A05155A5-7FA8-4213-86ED-8838A282571D
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Maria Trojano
@ast
Maria Trojano
@en
Maria Trojano
@es
Maria Trojano
@sl
type
label
Maria Trojano
@ast
Maria Trojano
@en
Maria Trojano
@es
Maria Trojano
@sl
altLabel
maria troiano
@en
prefLabel
Maria Trojano
@ast
Maria Trojano
@en
Maria Trojano
@es
Maria Trojano
@sl
P106
P1153
7005165969
P21
P31
P496
0000-0002-6329-8946